

B6  
1 second set of primers/probe specific for a housekeeping gene such as GAPDH which has been labeled with a different fluorophore on the 5' end (typically VIC). --

Please replace the paragraph beginning at page 115, line 32 with the following rewritten paragraph:

B17 To determine the level of 14094 in various human tissues a primer/probe set was designed. Total RNA was prepared from a series of human tissues using an RNeasy kit from Qiagen. First strand cDNA was prepared from 1 µg total RNA using an oligo-dT primer and Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained from approximately 50 ng total RNA was used per TAQMAN® reaction. Tissues tested include the human tissues and several cell lines shown in Tables 3-6. --

In the claims:

Pending claims are reiterated and claim 58 is amended as follows:

19. (reiterated) A method comprising:
- a) contacting a polypeptide that comprises the sequence of SEQ ID NO:12, or a cell expressing a polypeptide that comprises the sequence of SEQ ID NO:12 with a test compound; and
  - b) determining whether the polypeptide binds to the test compound.
54. (reiterated) The method of claim 19 wherein the contacting is in vitro.
55. (reiterated) The method of claim 19 wherein the contacting comprises contacting a cell expressing the polypeptide.
56. (reiterated) The method of claim 19 wherein the determining comprises directly detecting test compound/polypeptide binding.

57. (reiterated) The method of claim 19 wherein the determining comprises a competition binding assay.

B18 58. (amended) The method of claim 19 wherein binding of the polypeptide to the test compound is indicated by cleavage of the test compound.

59. (reiterated) The method of claim 19 wherein the test compound comprises a peptide.

60. (reiterated) The method of claim 19 wherein the test compound is fluorescently labeled.

61. (reiterated) The method of claim 19 wherein the test compound is a member of biological library.

62. (reiterated) The method of claim 19 wherein the test compound is attached to a bead.

Please add claims 63 to 68.

-- 63. (new) A method of evaluating interaction between a test compound and a polypeptide that comprises the sequence of SEQ ID NO:12, the method comprising:

a) contacting a polypeptide that comprises the sequence of SEQ ID NO:12, or a cell expressing a polypeptide that comprises the sequence of SEQ ID NO:12 with a test compound;  
and

B19 b) evaluating hydrolysis of the test compound.

64. (new) A method of evaluating interaction between a test compound and a polypeptide that comprises the sequence of SEQ ID NO:12, the method comprising:

a) contacting a polypeptide that comprises the sequence of SEQ ID NO:12, or a cell expressing a polypeptide that comprises the sequence of SEQ ID NO:12 with a test compound and a substrate; and

b) evaluating hydrolysis of the substrate in the presence of the test compound.

65. (new) The method of claim 19 wherein the test compound comprises a peptoid.

66. (new) The method of claim 19 wherein the test compound comprises a peptidomimetic.

67. (new) The method of claim 19 wherein the test compound is selected from the group consisting of: L-1-Chloro-3-tosylamido-4-phenyl-2-butanone, Soybean inhibitor, benzamidine, p-Nitrophenyl-p-guanidino benzoate, Tosyl-L-lysine chloromethyl ketone, and Tosyl-L-arginine chloromethyl ketone.

68. (new) The method of claim 19 wherein the test compound is a protein. --

In the drawings:

Please substitute the drawings with the accompanying formal drawings.